Author of

• 20182

  +

  P3.03 - Chemotherapy/Targeted Therapy (ID 719)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Chemotherapy/Targeted Therapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 24056

    +

    P3.03-011 - A Report of BRAF V600E Positive Lung Adenocarcinoma Patient Who Respond Well to Pemetrexed (ID 8806)

    09:30 - 16:00  |  Author(s): T. Shimizu
    • Abstract

    Background:
    BRAF mutations is one of the important driver oncogene in non-small cell lung cancer (NSCLC), and are known to give the petients worse prognosis as same as KRAS mutations. However, we experienced that a patient with BRAF V600E positive lung adenocarcinoma was responsive to pemetrexed treatment. The patient has been followed for over 7 years without recurrence and metastasis.
    
    Method:
    Here, we introduce a pemetrexed well respond patient with BRAF mutation positive lung adenocarcinoma. Clinical presentation, radiological features, histopathologic findings and genetic findings of the patient are reported.
    
    Result:
    A 64 years-old never smoker female who complained bloody sputum visited our hospital. Chest X ray examination showed protrusion of the right first aortic arches. Transbronchial lung biopsy was performed and primary lung adenocarcinoma was diagnosed. Brain metastasis was suspected by magnetic resonance imaging. The patient was initially given combined chemotherapy with CDDP+VNR and Radiation therapy (60Gy). But after six months, tumor progression was found. Therapeutic agent was changed to 600mg single pemetrexed as outpatient chemotherapy for 14 months. Computed tomography showed reduction of tumor mass. Then, the patient has been still followed without any anti-cancer treatment. It passed for 7 years after diagnosis. The oncogenic driver mutations of the present patient were investigated in another study. Immunohistochemistry and DNA sequencing analysis showed the existence of BRAF mutation V600E in the present case.
    
    Conclusion:
    BRAF mutation in NSCLC was reported not associated with enhanced chemosensitivity. However, pemetrexed was effective to the present BRAF V600E positive lung adenocarcinoma patient.